the induction dose of remimazolam combined with sufentanil for general anesthesia in severely obese patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500095487

Enrollment

Unknown

Registered

2025-01-08

Start date

2025-01-14

Completion date

Unknown

Last updated

2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obese

Interventions

Test group: Intravenous remimazolam was administered at a starting dose of 0.2mg/kg/2min two minutes after sufentanil 0.5ug/kg (calculated as LBW)was injected. The dose for the next patient was determ

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients scheduled for bariatric surgery, with a body mass index (BMI) more than kg/m², American Society of Anesthesiologists status (ASA) of ?-?,aged 18 to 60 years, gived writtern informed consent.

Exclusion criteria

Exclusion criteria: Refused to provide informed consent, uncontrolled hypertension,chronic heart failure, significantly impaired hepatic or renal function, difficult mask ventilation, preoperative cognitive impairment.

Design outcomes

Primary

Measure	Time frame
MOAS/S;Rimazolen ED50;	—

Secondary

Measure	Time frame
BIS;blood pressure;heart rate;	—

Countries

China

Contacts

Public ContactChen Minghui

Shanghai Tenth People's Hospital

cmhkeky@126.com+86 159 2135 0209

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026